Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead

Core Viewpoint - Takeda announced improved earnings results for Q3 FY2025, highlighting a narrowing gap between incremental Growth & Launch Products revenue and VYVANSE erosion, alongside operational efficiencies leading to reduced operating expenses [1] Financial Performance - The company reported year-on-year reductions in operating expenses, including R&D, indicating effective cost management strategies [1] - Takeda raised its full-year forecasts, attributing this to cost discipline and favorable foreign exchange (FX) conditions [1] Revenue Management - The narrowing gap between Growth & Launch Products revenue and VYVANSE erosion suggests a positive trend in product performance and revenue management [1]